Business Context and Reporting Period
Company: Allogene Therapeutics, Inc. (ALLO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Allogene is a clinical-stage immuno-oncology company developing "off-the-shelf" allogeneic CAR T cell therapies for cancer and autoimmune diseases. The company focuses on three core programs: cema-cel (ALPHA3 trial) for Large B-Cell Lymphoma (LBCL), ALLO-316 (TRAVERSE trial) for Renal Cell Carcinoma (RCC), and ALLO-329 (RESOLUTION trial) for autoimmune diseases.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $22,000 |
| Net Loss | $(190.9) million | $(257.6) million |
| Operating Expenses | $209.3 million | $273.2 million |
| Cash, Cash Equivalents & Investments | $258.3 million | $368.7 million |
| Accumulated Deficit | $(2.01) billion | $(1.82) billion |
| Stockholders' Equity | $292.5 million | $422.2 million |
Note: Revenue in 2024 was derived from a related-party collaboration agreement with Overland Therapeutics. No product sales revenue was generated in either period.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $66.7 million (26%) compared to 2024, driven primarily by a $42.1 million reduction in Research and Development (R&D) expenses and an $8.4 million reduction in General and Administrative (G&A) expenses.
- Cost Reduction Initiatives: In May 2025, the company implemented a workforce reduction affecting approximately 28% of employees (61 employees), resulting in $3.3 million in cash-based severance expenses and $1.3 million in equipment impairment charges.
- Impairment Charges: Long-lived asset impairment charges decreased significantly from $15.7 million in 2024 to $2.4 million in 2025, related to subleased properties and equipment.
- Cash Position: Cash and investments declined by approximately $110 million year-over-year due to operating cash outflows of $149.2 million, partially offset by financing activities (ATM offerings and CIRM awards) totaling $30.2 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Cash Runway: Management expects current cash resources ($258.3 million) to fund operations into the first quarter of 2028.
- Clinical Milestones:
- ALPHA3 (cema-cel): An interim futility analysis comparing MRD clearance rates is expected in April 2026. Enrollment is anticipated to complete by the end of 2027.
- TRAVERSE (ALLO-316): Enrollment in the Phase 1b expansion cohort is complete. The company is exploring strategic partnerships.
- RESOLUTION (ALLO-329): Initial proof-of-concept data is expected in June 2026.
Material Risks and Contingencies
- Safety Event in ALPHA3: In August 2025, the FCA arm (fludarabine, cyclophosphamide, and ALLO-647) of the ALPHA3 trial was discontinued following a Grade 5 serious adverse event (fulminant hepatic failure) attributed to the anti-CD52 antibody ALLO-647. The trial now proceeds with only the FC arm (standard lymphodepletion) and observation. Development of ALLO-647 has been terminated.
- Intellectual Property Litigation: Factor Bioscience filed a lawsuit against Cellectis (Allogene's TALEN gene-editing technology licensor) alleging patent infringement. While Allogene is not a named defendant, a ruling against Cellectis could require Allogene to seek a new license or abandon its TALEN-based programs (cema-cel, ALLO-316).
- Companion Diagnostic Reliance: The ALPHA3 trial relies on the CLARITY MRD assay developed by Foresight Diagnostics (acquired by Natera in Dec 2025). Delays in regulatory approval or operational disruptions of this assay could hinder trial enrollment and commercialization.
- Manufacturing Scale-down: Reduced manufacturing operations and workforce reductions introduce risks regarding the retention of technical expertise and the ability to ramp up production for commercialization.
Investor Verification Checklist
- Capital Adequacy: Verify the accuracy of the Q1 2028 cash runway projection given the high burn rate and potential for unforeseen clinical costs.
- ALPHA3 Trial Design: Confirm the statistical power and regulatory acceptance of the amended ALPHA3 trial design (FC arm only) following the discontinuation of the FCA arm.
- IP Litigation Status: Monitor the progress of the Factor Bioscience vs. Cellectis litigation and any potential impact on Allogene's access to TALEN technology.
- Partnership Progress: Assess the status of potential strategic partnerships for ALLO-316 and the joint venture with Overland Therapeutics, given the company's need for additional capital.
- Manufacturing Readiness: Evaluate the impact of the May 2025 workforce reduction on the company's ability to scale manufacturing for commercial launch if approval is granted.